Trial Profile
Efficacy and safety of carboplatin and pemetrexed for the first-line treatment of patients with nonsquamous non-small cell lung cancer unfit to receive cisplatin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Dec 2015 New trial record